10 October 2019
UCB to acquire Ra Pharmaceuticals in $2.1bn deal
Belgian biopharmaceutical firm UCB has signed a merger agreement to acquire US-based Ra Pharmaceuticals for $48 per share, totalling $2.1bn in cash.
Focus:
News
-
9 October 2019
ICER finds lack of evidence to support blockbuster drug price hikes
A report by the Institute of Clinical and Economic Review (ICER) has determined that seven of the nine top-selling drugs in the US had limited new clinical evidence of greater...
-
9 October 2019
GSK and Lyell partner to develop cell therapies for cancer
GlaxoSmithKline (GSK) has partnered with US-based biotechnology firm Lyell Immunopharma to develop technologies to boost cancer cell therapies.
-
9 October 2019
J&J’s Janssen to pay $8bn in Risperdal anti-psychotic drug lawsuit
A jury at Philadelphia Court of Common Pleas has ordered Johnson & Johnson (J&J) subsidiary Janssen Pharmaceuticals to pay $8bn in punitive damages over its marketing of Risperdal, an anti-psychotic...
-
9 October 2019
Novartis receives FDA approval for Beovu to treat wet AMD
Novartis has secured the US Food and Drug Administration (FDA) approval for the use of its Beovu (brolucizumab) medicine to treat wet age-related macular degeneration (AMD).
-
8 October 2019
Pfizer licenses Akcea’s ANTPTL3-targetting drug for $250m
Pfizer and Ionis subsidiary Akcea have signed a global exclusive licensing agreement for antisense therapy AKCEA-ANGPTL3-LRx.
-
7 October 2019
UK Government invests £35m into researching adolescent mental health
The UK Government has launched a research project into understanding the causes of mental health problems in teenagers and young adults, including the genetics and societal influences underpinning why some...
-
7 October 2019
J&J to invest $500m in HIV and TB therapies research
Johnson & Johnson (J&J) has announced plans to invest over $500m towards research and development of HIV and tuberculosis (TB) vaccines.
-
7 October 2019
UK study finds drug that could help treat aggressive breast cancers
A study by researchers at The Institute of Cancer Research, London (ICR), has revealed that a drug, BOS172722, could help boost chemotherapy response in aggressive breast cancers that have become...
-
7 October 2019
FDA approves self-administration of AstraZeneca’s asthma drug
The US Food and Drug Administration (FDA) has approved self-administration AstraZeneca's asthma drug Fasenra, a pre-filled, single-use auto-injector.
Close
Close
Close
Go Top
